Changes to SRED Program Threaten Canada's Global Competitiveness
![]()

Following numerous discussions and activities over the last six months, and recent rumours circling around on this topic, it is time to comment. I am deeply concerned about the potential changes to the Scientific Research and Experimental Development—or "SRED"—program in the upcoming Federal Budget, and the impact such changes could have on R&D investment, commercialization, and Canada’s competitiveness.
To be clear on my vested interest, I speak from my personal perspective as an early stage entrepreneur and investor—not as an advisor in a professional services firm. Having spent 20 years in the Canadian technology industry, I have been fortunate to visit dozens of technology centres around the world and had a chance to gauge our global competitiveness as an industry.
read more
There's no question that Canadian entrepreneur Kevin O'Leary is an asshole. But he's earned the right to be one.
Stem cells are all the rage these days, and it’s not just a medical fad. With the ability to differentiate themselves into just about any other type of cell in the human body, they can be used to combat cancer, multiple sclerosis, Parkinson’s disease, and many conditions.
There’s an experimental drug in the works that has been able to kill cancer cells. It’s called Dichloroacetate (DCA), and it’s being refined and perfected at the University of Alberta.
Almost everyone is familiar with the powerful effects of 3D technology in blockbuster films—when done right—such as Avatar in 2009 and multiple Academy Award-winning Hugo last year (the latter was was
Curiosity is a difficult temptation to resist. Some hands-on research from Symantec
Expecting a bad quarter from RIM? You may as well expect a bad year.